Widely read:
Stockwire
• Wealth Insight - May 2025
Analyst's Diary: Who's making your medicine?
The different drug development stages and the companies behind them
01-May-2025•Abhinav Goel
Top Picks
The Rs 5,000 cap on global funds barely matters
4 min read•By Aakar Rastogi
Welcome to the New Value Research!
2 min read•By Value Research
33 min read•By Abhinav Goel
New episodes every Friday
The slow learner
A business can improve in plain sight for years before its price admits it
Other Episodes
-
The AI revolution worth having
Forget the trillions being bet on AI. The revolution that matters is the one you can build for yourself, for free, right now.
-
Old file, new company
The market misprices stocks using outdated assumptions. The opportunity lies in that gap.
-
When 'this too shall pass' doesn't
For 30 years, I have told readers to ride out every crisis. The US-Iran war is the exception, and the reason matters more than the news itself.
-
Read the signal, not the list
The Prime Minister's seven appeals are about consumption. The signal they carry is about the rupee.
More stories from Wealth Insight May 2025
Explore the edition
When markets fall, look within
3 min read•By Dhirendra Kumar
5 traps turning your portfolio red
13 min read•By Udhayaprakash
5 min read•By Value Research Team
'Diversification helps during volatile times'
10 min read•By Value Research Team
Market Reporter: Who made the news?
1 min read•By Value Research Team
1 min read•By Value Research Team
Market Barometer: The metrics that matter
1 min read•By Value Research Team
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
